IL296168A - Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters - Google Patents
Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transportersInfo
- Publication number
- IL296168A IL296168A IL296168A IL29616822A IL296168A IL 296168 A IL296168 A IL 296168A IL 296168 A IL296168 A IL 296168A IL 29616822 A IL29616822 A IL 29616822A IL 296168 A IL296168 A IL 296168A
- Authority
- IL
- Israel
- Prior art keywords
- snp
- rsl2217173
- treatment
- transporter
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986603P | 2020-03-06 | 2020-03-06 | |
| PCT/US2021/019265 WO2021178166A1 (en) | 2020-03-06 | 2021-02-23 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296168A true IL296168A (en) | 2022-11-01 |
Family
ID=77613738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296168A IL296168A (en) | 2020-03-06 | 2021-02-23 | Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12612661B2 (https=) |
| EP (1) | EP4106872A4 (https=) |
| JP (1) | JP2023515665A (https=) |
| KR (1) | KR20230005816A (https=) |
| CN (1) | CN115515680A (https=) |
| AR (1) | AR121515A1 (https=) |
| AU (1) | AU2021231683A1 (https=) |
| BR (1) | BR112022017770A2 (https=) |
| CA (1) | CA3174572A1 (https=) |
| IL (1) | IL296168A (https=) |
| MX (1) | MX2022010816A (https=) |
| TW (1) | TW202146660A (https=) |
| WO (1) | WO2021178166A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| CN114848835B (zh) * | 2022-03-22 | 2023-08-25 | 暨南大学 | 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6945457B1 (en) * | 1996-05-10 | 2005-09-20 | Transaction Holdings Ltd. L.L.C. | Automated transaction machine |
| JP4198582B2 (ja) * | 2003-12-02 | 2008-12-17 | 独立行政法人科学技術振興機構 | タンタルオキシナイトライド酸素還元電極触媒 |
| WO2007128884A1 (en) * | 2006-05-09 | 2007-11-15 | Oy Jurilab Ltd | Novel genes and markers in type 2 diabetes and obesity |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2008065544A2 (en) | 2006-09-11 | 2008-06-05 | Mcgill University | Genetic predictors of risk for type 2 diabetes mellitus |
| EP2243834A1 (en) | 2007-03-05 | 2010-10-27 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| US20170029892A1 (en) | 2009-05-29 | 2017-02-02 | Jay L. Lombard | Methods and compositions for the treatment of post-traumatic stress disorder |
| US8355927B2 (en) * | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| EP2707498B1 (en) | 2011-01-31 | 2018-01-17 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| WO2012156515A1 (en) * | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| CA2838207A1 (en) | 2011-06-08 | 2012-12-13 | Denovo Biopharma (Hangzhou) Ltd. Co. | Methods and compositions of predicting activity of retinoid x receptor modulator |
| US20140274764A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| US20170253928A1 (en) | 2013-03-15 | 2017-09-07 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| TR201907106T4 (tr) | 2014-03-14 | 2019-06-21 | Caredx Inc | Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri. |
-
2021
- 2021-02-23 CA CA3174572A patent/CA3174572A1/en active Pending
- 2021-02-23 KR KR1020227034374A patent/KR20230005816A/ko active Pending
- 2021-02-23 EP EP21764344.4A patent/EP4106872A4/en active Pending
- 2021-02-23 BR BR112022017770A patent/BR112022017770A2/pt unknown
- 2021-02-23 AU AU2021231683A patent/AU2021231683A1/en active Pending
- 2021-02-23 JP JP2022552541A patent/JP2023515665A/ja active Pending
- 2021-02-23 WO PCT/US2021/019265 patent/WO2021178166A1/en not_active Ceased
- 2021-02-23 IL IL296168A patent/IL296168A/en unknown
- 2021-02-23 US US17/905,511 patent/US12612661B2/en active Active
- 2021-02-23 MX MX2022010816A patent/MX2022010816A/es unknown
- 2021-02-23 CN CN202180031602.1A patent/CN115515680A/zh active Pending
- 2021-03-05 AR ARP210100576A patent/AR121515A1/es unknown
- 2021-03-05 TW TW110107927A patent/TW202146660A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12612661B2 (en) | 2026-04-28 |
| CN115515680A (zh) | 2022-12-23 |
| WO2021178166A1 (en) | 2021-09-10 |
| CA3174572A1 (en) | 2021-09-10 |
| US20230193388A1 (en) | 2023-06-22 |
| MX2022010816A (es) | 2022-12-13 |
| BR112022017770A2 (pt) | 2022-11-29 |
| JP2023515665A (ja) | 2023-04-13 |
| TW202146660A (zh) | 2021-12-16 |
| EP4106872A4 (en) | 2024-04-10 |
| EP4106872A1 (en) | 2022-12-28 |
| KR20230005816A (ko) | 2023-01-10 |
| AU2021231683A1 (en) | 2022-09-22 |
| AR121515A1 (es) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210108266A1 (en) | Method for discovering pharmacogenomic biomarkers | |
| US20230074781A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| KR20140039278A (ko) | 레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물 | |
| JP2022550905A (ja) | circRNAを検出する方法 | |
| IL296168A (en) | Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters | |
| KR102033813B1 (ko) | 항정신병약물-베이스 치료에 의하여 유발된 추체외로 증상 (eps)의 개시를 예측하는 방법 | |
| Yang et al. | A large pedigree study confirmed the CGG repeat expansion of RILPL1 Is associated with oculopharyngodistal myopathy | |
| JP2010515467A (ja) | 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム | |
| HK40083504A (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| Sabbatini | Identificazione e caratterizzazione dei modificatori genetici della DMD | |
| Federoff | An investigation into the genetic architecture of multiple system atrophy and familial Parkinson's disease | |
| 이진숙 | Whole exome sequencing-based discovery of causative genes | |
| HK40011257B (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| HK40011257A (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| Chien | Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease | |
| HK1196399B (en) | Method for discovering pharmacogenomic biomarkers | |
| HK1196399A (en) | Method for discovering pharmacogenomic biomarkers |